How Is The Malignant Mesothelioma Market Expected To Grow At 6.3% CAGR Over 2025–2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Is The Malignant Mesothelioma Market Expected To Grow In Terms Of Size?
In recent times, there has been significant growth in the size of the malignant mesothelioma market. This market, valued at $2.46 billion in 2024, is projected to expand to $2.61 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.9%. Factors contributing to this growth over the historical period include an increase in oncology research investment, a surge in legal proceedings related to asbestos, growth in hospital investments, a rise in the elderly population, and advancements in artificial intelligence-based drug discovery platforms.
The market for malignant mesothelioma is predicted to witness impressive expansion over the coming years, swelling to a value of $3.32 billion by 2029, with a compound annual growth rate of 6.3%. Several factors contributing to this projected growth in the outlined period include higher adoption of immunotherapy approaches, an augmented emphasis on personalized healthcare, an increased tendency towards less invasive surgical methods, escalated health spending, and a rise in clinical trials. Key trends directing the future of this market revolve around advancements in immunotherapy and personalized medicine, innovations for early disease detection, the evolution of less invasive surgical practices, and regulatory authorizations.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22046&type=smp
What Are The Primary Factors Supporting The Malignant Mesothelioma Market Expansion?
The growth of the malignant mesothelioma market is anticipated to be bolstered by the rise in clinical research and development initiatives. The process of clinical R&D involves undertaking scientific examinations and experiments to formulate novel drugs, treatments and medical instruments. This involves assessing novel products for safety, effectiveness and any potential side effects through carefully controlled clinical trials. The surge in such clinical R&D initiatives can be attributed to the escalating demand for new and enhanced treatments, particularly in response to the increasing incidence of chronic illnesses and complicated conditions. R&D initiatives contribute to the malignant mesothelioma market by hastening progress in diagnosis, treatments, and precise therapies, thereby encouraging novel ways to ameliorate early detection, augment survival rates, and devise more efficient, less intrusive treatment alternatives. For instance, as reported by Anadolu Agency, a state-run news agency based in Turkey, in January 2025, clinical trials constitute close to 40% of the US pharmaceutical research budget, amounting to around $7 billion annually. Consequently, the rise in research and development initiatives is propelling the growth of the malignant mesothelioma market.
Which Segmentation Categories Are Highlighted In The Malignant Mesothelioma Market Analysis?
The malignant mesotheliomamarket covered in this report is segmented –
1) By Treatment Type: Chemotherapy; Radiation Therapy; Surgery; Immunotherapy; Targeted Therapy
2) By Route Of Administration: Oral; Intravenous; Injectable; Topical
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
4) By End-User: Hospitals; Oncology Clinics; Rehabilitation Centres; Research Laboratories
Subsegments:
1) By Chemotherapy: Alkylating Agents; Antimetabolites; Combination Therapy
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Intensity-Modulated Radiation Therapy (IMRT); Stereotactic Body Radiation Therapy (SBRT); Proton Therapy
3) By Surgery: Pleurectomy Or Decortication (P/D); Extrapleural Pneumonectomy (EPP); Cytoreductive Surgery; Palliative Surgery
4) By Immunotherapy: Immune Checkpoint Inhibitors; Monoclonal Antibodies; Tumor Vaccines; Adoptive Cell Therapy
5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Angiogenesis Inhibitors; Mesothelin-Targeted Agents; Gene Therapy-Based Approaches
Which Notable Trends Are Transforming The Malignant Mesothelioma Market Outlook?
Companies in the malignant mesothelioma market are working on innovative treatment options such as monoclonal antibody therapies aimed at inhibiting tumor growth and improving treatment precision. Monoclonal antibodies are lab-produced proteins that imitate the immune system’s ability to identify and target specific antigens on cancer cells. For example, in November 2023, Japan-based Ono Pharmaceutical Co. Ltd. received supplemental approval for Opdivo (nivolumab), a human anti-PD-1 monoclonal antibody, for treating malignant mesothelioma (excluding malignant pleural mesothelioma). This approval introduces Opdivo as a new treatment option for this condition, which previously lacked standard therapies. Opdivo was granted orphan drug status for this indication, underscoring its potential to meet a significant medical need.
Which Organizations Are At The Forefront Of The Malignant Mesothelioma Market?
Major companies operating in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report
Which Geographic Regions Are Creating Strong Demand In The Malignant Mesothelioma Market?
North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=22046&type=smp
Browse Through More Reports Similar to the Global Malignant Mesothelioma Market 2025, By The Business Research Company
Lung Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report
Lung Cancer Diagnostic And Screening Global Market Report 2025
Small Cell Lung Cancer Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
